SpotDraft was founded in 2017 by Carnegie Mellon graduate Madhav Bhagat and Harvard Law School alumnus Shashank Bijapur with ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

BMO Capital Markets maintained its Outperform rating and $545.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), representing a 16% upside from the current price of $469.97. With a ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Taser maker Axon sees AI-related sales take off and its drone business gain momentum. Axon stock is near a buy point.

Plus, developers and subscribers can try Gemini 2.0 Pro Experimental. A lighter, cheaper model, Gemini 2.0 Flash-Lite, hit ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...